Phase 2 study of the safety and tolerability of maraviroc-containing regimens to prevent HIV infection in men who have sex with men (MSM) (HPTN 069/ACTG A5305)

Topic:

HIV Prevention

Authors:

Gulick RM, Wilkin TJ, Chen YQ, Landovitz RJ, Amico KR, Young AM, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, McGowan I, Cottle LM, Andrade A, Marcus C, Klingman KL, Chege W, Rinehart AR, Rooney JF, Andrew P, Salata RA, Magnus M, Farley JE, Liu A, Frank I, Ho K, Santana J, Stekler JD, McCauley M, Mayer KH.

External Link:

Link to article

BACKGROUND:

Maraviroc (MVC) is a candidate for HIV pre-exposure prophylaxis (PrEP).

METHODS:

Phase 2 48-week safety/tolerability study of four regimens: MVC alone, MVC+emtricitabine (FTC), MVC+tenofovir disoproxil fumarate (TDF), and TDF+FTC. Eligible participants were HIV-uninfected men and transgender women reporting condomless anal intercourse with >1 HIV-infected or unknown-serostatus man within 90 days. At each visit, assessments, laboratory testing, and counseling were done. Analyses were intention-to-treat. Registry #NCT01505114 RESULTS:  Among 406 participants, 84% completed follow-up, 7% stopped early, and 9% were lost-to-follow-up; 9% discontinued their regimen early. The number discontinuing and time-to-discontinuation did not differ among study regimens (p=0.60). Grade 3-4 adverse event rates did not differ among regimens (p=0.37). In a randomly-selected subset, 77% demonstrated detectable drug concentrations at week 48. Five participants acquired HIV infection (4 MVC alone, 1 MVC+TDF; overall annualized incidence 1.4% [95% CI:0.5%, 3.3%], without differences by regimen, p=0.32); 2 had undetectable drug concentrations at every visit, 2 had low concentrations at the seroconversion visit, and 1 had variable concentrations.

CONCLUSIONS:

MVC-containing regimens were safe and well-tolerated compared to TDF+FTC; this study was not powered for efficacy. Among those acquiring HIV infection, drug concentrations were absent, low, or variable. MVC-containing regimens may warrant further study for PrEP.

J Infect Dis. 2016 Nov 2. pii: jiw525. [Epub ahead of print]
PMID: 27811319

Categories

CRS
Topics

Clinical Trials

A5342: Evaluating the Safety, Tolerability, and Effect of a...

The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...

Read More

A5350: Effects of Visbiome Extra Strength on Gut Microbiome...

Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...

Read More

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More

A5329: Interferon –Free Therapy for Chronic Hepatitis C...

A5329 is a study for people who are infected with both HIV and the Hepatitis C virus (HCV) and have never taken Hepatitis C...

Read More

P1077BF: Breastfeeding Version of the PROMISE Study...

1077BF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More